By Sheri Kasprzak
New York, June 2 - NicOx SA has wrapped up a €15 million stock deal with Pfizer, Inc.
Pfizer bought 1,350,135 shares at €11.11 each, a 4.9% premium to the average closing prices for the 20 trading days before closing.
The offering was conducted as part of an agreement between the two companies in which Pfizer was granted the exclusive right to apply NicOx's nitric oxide-donating technology in the field of ophthalmology. For the agreement, NicOx may receive up to €300 million plus royalties.
Located in Sophia Antipolis, France, NicOx is a biopharmaceutical company focused on developing nitric oxide-donating drugs used to treat inflammatory and cardio-metabolic disorders.
| Issuer: | NicOx SA
|
| Issue: | Stock
|
| Amount: | €15 million
|
| Shares: | 1,350,135
|
| Price: | €11.11
|
| Warrants: | No
|
| Investor: | Pfizer, Inc.
|
| Settlement date: | June 2
|
| Stock symbol: | Frankfurt: NXO
|
| Stock price: | €11.76 at close June 1
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
